Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure

Cristiano Fava, Martina Montagnana, Lena Nilsson, Philippe Burri, Peter Almgren, A Jonsson, P Wanby, G Lippi, P Minuz, Lennart Hulthén, M Aurell, Olle Melander

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

51 Citeringar (SciVal)

Sammanfattning

Gitelmans syndrome (GS) is an inherited recessive disorder caused by homozygous or compound heterozygous loss of function mutations of the NaCl cotransporter (NCCT) gene encoding the kidney-expressed NCCT, the pharmacological target of thiazide diuretics. An observational study estimated the prevalence of GS to 19/1 000 000, in Sweden, suggesting that similar to 1% of the population carries one mutant NCCT allele. As the phenotype of GS patients, who always carry two mutant alleles, is indistinguishable from that seen in patients treated with high-dose thiazide diuretics, we aimed at investigating whether subjects carrying one mutated NCCT allele have a phenotype resembling that of treatment with low-dose thiazide diuretics. We screened first-degree relatives of 18 of our patients with an established clinical end genetic diagnosis of GS for NCCT loss of function mutations and identified 35 healthy subjects carrying one mutant allele (GS-heterozygotes). Each GS-heterozygote was assigned a healthy control subject matched for age, BMI and sex. GS-heterozygotes had markedly lower blood pressure (systolic 103.3 +/- 16.4 versus 123.2 +/- 19.4 mmHg; diastolic 62.5 +/- 10.5 versus 73.1 +/- 9.4 mmHg; P < 0.001) than controls. There was no significant difference between the groups either in plasma concentration or urinary excretion rate of electrolytes, however, GS-heterozygotes had higher fasting plasma glucose concentration. Similar to patients being treated with low-dose thiazide diuretics, GS-heterozygotes have markedly lower blood pressure and slightly higher fasting plasma glucose compared with control subjects. Our findings suggest that GS-heterozygotes, the prevalence of which can be estimated to 1%, are partially protected from hypertension through partial genetic loss of function of the NCCT. However, as our study had a case-control design, it is important to underline that any potential effects on population blood pressure and risk of future cardiovascular disease need to be examined in prospective and population-based studies.
Originalspråkengelska
Sidor (från-till)413-418
TidskriftHuman Molecular Genetics
Volym17
Utgåva3
DOI
StatusPublished - 2008

Bibliografisk information

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Hypertension and Cardiovascular Disease (013242540), Pediatrics/Urology/Gynecology/Endocrinology (013240400), Diabetes and Endocrinology (013241530)

Ämnesklassifikation (UKÄ)

  • Medicinsk genetik

Fingeravtryck

Utforska forskningsämnen för ”Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här